DurgicalDurgical
EN
Open the app

Pharmacology · Direct oral anticoagulants (DOACs)

Dabigatran !

An oral anticoagulant that blocks thrombin directly. It is cleared mainly by the kidneys and has its own antidote, idarucizumab.

Updated 2026-11-01

Also called: dabigatran etexilate

The figure shows a dabigatran-series inhibitor (the ethyl ester of the dabigatran molecule) in thrombin's active site; the crystal also holds a hirudin fragment.

Target in 3D: Thrombin (coagulation factor IIa). PDB structure 1KTS (RCSB PDB, public domain). View the structure at RCSB PDB

Mechanism of action

Dabigatran etexilate is a prodrug that esterases convert into dabigatran. Dabigatran is a direct thrombin inhibitor: it blocks both free thrombin and thrombin bound inside the clot. Thrombin can then no longer turn fibrinogen into fibrin, and thrombin-driven platelet aggregation falls.

  1. Esterases turn the prodrug into active dabigatran
  2. Dabigatran blocks thrombin, free and inside the clot
  3. Less fibrin forms and platelets aggregate less
  4. Clots form and grow less: lower risk of stroke and VTE

Pharmacokinetics

Absorption
Low oral bioavailability; capsules are swallowed whole, since opening or chewing them raises exposure.
Distribution
Low binding to plasma proteins, so haemodialysis can remove part of it.
Metabolism
Not a CYP substrate; partly conjugated to active acyl glucuronides. The prodrug is a P-glycoprotein substrate.
Elimination
Mainly by the kidneys (about 80% of its clearance).
Half-life
About 12 to 17 hours, longer in kidney impairment.
Onset and duration
Peak levels about an hour after a dose, later with a fatty meal.

Indications

Adverse effects

Common

  • Dyspepsia and gastritis-like symptoms (heartburn, upper abdominal pain)
  • Bleeding (bruising, nose, gums)
  • Nausea

Contraindications

  • Mechanical prosthetic heart valves
  • Active pathological bleeding
  • Serious allergy to dabigatran
  • Triple-positive antiphospholipid syndrome (not recommended)

Key interactions

P-glycoprotein inhibitors (dronedarone, ketoconazole)
Raise dabigatran levels, most of all when kidney function is reduced.
P-glycoprotein inducers (rifampicin)
Lower levels and the protection against clots; generally avoided.
Aspirin, clopidogrel, prasugrel, ticagrelor and NSAIDs
Add to bleeding risk.

What is monitored

  • Kidney function before and during treatment
  • Signs of bleeding
  • The INR is insensitive to dabigatran; the aPTT or ecarin clotting time are used when its effect must be judged

Test yourself

Think of the answer, then tap the question to see it.

What is the specific antidote for dabigatran and how does it work?

Idarucizumab, a humanised antibody fragment that binds dabigatran more tightly than dabigatran binds thrombin, neutralising its effect.

Why does kidney function weigh more for dabigatran than for other DOACs?

The kidneys handle most of its clearance, so in kidney impairment it builds up, its half-life lengthens and bleeding risk rises.

Why are dabigatran capsules not opened?

Opening, breaking or chewing them increases how much is absorbed, raising exposure and bleeding risk.

Which adverse effects are most common with dabigatran?

Gastrointestinal symptoms such as dyspepsia and gastritis-like discomfort, and bleeding.

Add to my cards (4)

← Back to the class: Direct oral anticoagulants (DOACs)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: DailyMed - DABIGATRAN- dabigatran etexilate capsule (DailyMed (U.S. National Library of Medicine), 2026); Dabigatran: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); eEML - Electronic Essential Medicines List (World Health Organization, 2025).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.